Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | MLNR | O43193 | 17/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31282708 | 0.83 | DRD2 (0.42) | DRD2SLC6A4CYP3A4DDB1CRBN | |
| SCHEMBL31281965 | 0.83 | DRD2 (0.39) | DRD2SLC6A4CYP3A4DDB1CRBN | |
| SCHEMBL31282081 | 0.83 | DRD2 (0.44) | DRD2SLC6A4CYP3A4DDB1CRBN | |
| SCHEMBL31281909 | 0.82 | DRD2 (0.41) | DRD2SLC6A4CYP3A4DDB1CRBN | |
| SCHEMBL31282427 | 0.82 | DRD2 (0.41) | DRD2SLC6A4CYP3A4DDB1CRBN | |
| SCHEMBL31282370 | 0.81 | DRD2 (0.40) | DRD2SLC6A4CYP3A4DDB1CRBN | |
| SCHEMBL31282557 | 0.81 | DRD2 (0.36) | DRD2SLC6A4CYP3A4DDB1CRBN | |
| SCHEMBL31281895 | 0.79 | DRD2 (0.35) | DRD2SLC6A4CYP3A4CYP2D6DDB1 | |
| SCHEMBL31282093 | 0.78 | DRD2 (0.38) | DRD2SLC6A4CYP3A4DDB1CRBN | |
| SCHEMBL31281914 | 0.78 | DRD2 (0.38) | DRD2SLC6A4CYP3A4DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024019103-A1 | HETEROCYCLIC COMPOUND THAT ACTS ON G12D MUTANT KRAS PROTEIN | アステラス製薬株式会社 | 2024-01-25 | — | — | WO | disclosed |